Translating cancer biology into medicines

Cell cycle pioneers improving patients' healthcare
with innovative medicines

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) is a biopharmaceutical company developing innovative therapies that target various phases of cell cycle control for the treatment of cancer and other serious diseases.

Our strategy is to build a diversified portfolio of novel drug candidates to address areas of high unmet medical needs.

Our Pipeline

Cyclacel is a pioneer in the field of cell cycle biology. Our vision is to improve patient healthcare by translating cancer biology into medicines. We have three programs in development:

  • A transcriptional regulation program is evaluating lead asset CYC065, a dual inhibitor of cyclin dependent kinases (CDK) 2 and 9, in patients with advanced cancers.
  • A mitosis regulation program is investigating CYC140, a polo-like kinase 1 inhibitor, in cancer patients.
  • A DNA damage response program is evaluating a sequential regimen of sapacitabine and seliciclib, Cyclacel's first generation CDK inhibitor, in patients with BRCA positive, advanced solid cancers.

Our clinical programs are enhanced through collaboration with world renowned cancer research organizations such as MD Anderson Cancer Center and Dana Farber Cancer Institute.

Learn more about our clinical trials:


A highly-selective, orally-available, 2nd generation inhibitor of cyclin dependent kinases (CDK) 2 and 9.


A highly selective inhibitor of a mitotic pathway enzyme polo-like kinase 1.

CYC682 (Sapacitabine)

An oral nucleoside analogue prodrug that acts through a novel mechanism.

Common Stock Info




Delayed at least 20 minutes.
Provided by Nasdaq.

Interview of CEO Spiro Rombotis with Proactive Investors at the 11th Biotech Showcase in SFO